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Guillain-Barre’ Syndrome is a neurological syndrome that impacts nearly 100,000 patients yearly. 
This disease is a severe neuropathy resulting in rapidly ascending paralysis. The presentation of 
Guillain-Barre’ varies depending on the subtype and the region where it is contracted. Antecedent 
events for Guillain-Barre’s Syndrome are not fully understood, but these  are known to include 
bacterial or viral infections and rarely, immunizations.  (Willison et al, 2016). Evidence suggests 
that molecular mimicry may be a component of antecedent event response, particularly in 
Campylobacter jejuni infections (Van Doorn, et al 2010).  Pathophysiology of the condition differs 
between the axonal and demyelinating subtypes, as does length of recovery (Willison et al, 2016). 
Treatment is guideline-based and is centered around immunotherapy with either immune globulin 
administration or plasma exchange. (Hughes et al, 2003). Guillain-Barre’ Syndrome presents a 
unique opportunity for pharmacists to educate patients and providers, lead evidence-based and 
patient-specific care, and to support patients in the recovery process through excellent symptoms 
management.  
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OBJECTIVES
At the completion of this presentation, participants should be able to:
Review the proposed pathophysiology of Guillain-Barre’ Syndrome
Name the subtypes of Guillain-Barre’ Syndrome and differentiate between them
Know the diagnostic criteria and labs needed to identify Guillain-Barre’ Syndrome
Recommend appropriate treatment options for patients with Guillain-Barre’ Syndrome
Discuss the role of the pharmacist in Guillain-Barre’ Syndrome
PATIENT CASE
David is a 56 year old male who has received his influenza vaccine two weeks ago. He presents to the emergency 
room today with his wife, complaining of tingling and numbness in his feet and legs. He states that the numbness is 
worsening, and he feels increasingly weak. 
Vitals:  BP= 137/82   Weight: 200 lbs   Height: 6’2”   RR: 16       HR: 96 bpm
PMH: Hypertension, Type II Diabetes mellitus
PSH: Wisdom teeth removal 
Home medications: Metformin
What risk factors does David have for Guillain-Barre’ Syndrome?
GUILLAIN-BARRE’ SYNDROME
Autoimmune polyradiculoneuropathy that is often life-threatening
Characterized by progressive weakness and paralysis
Occurrence rate is 0.001-0.004%
Mortality ranges from 3-7%
Subtypes
Acute Inflammatory Demyelinating Polyneuropathy (AIDP)
Acute Motor Sensory Axonal Neuropathy (AMSAN)
Acute Motor Axonal Neuropathy (AMAN)
Miller Fischer Syndrome
Regional Variants
Hauser, S.,  Harrison’s Principles of Internal 
Medicine, 20th edition, 2018, Chapter 439. 
Willison, H. The Lancet, August 2016,  
388(10045):717-727.
Misawa, S., The Lancet Neurology, 17(6), 519-
529
DEMOGRAPHICS AND ASSOCIATED CONDITIONS
Males > Females
Adults > Children (in Western Countries)
More commonly seen in patients with HIV, systemic lupus erythematosus (SLE), or lymphomas
85% of patients make a full recovery in months to a year following their illness
Risk for developing GBS increases with age
Worse prognosis is associated with:
Age >40 years
Severe disability at most serious disease state
Diarrheal episode prior to GBS presentation
Hauser, S.,  Harrison’s Principles of 
Internal Medicine, 20th edition, 2018, 
Chapter 439..
Willison, H. The Lancet, August 2016,  
388(10045):717-727.
SIGNS AND SYMPTOMS
Rapidly progressing, motor paralysis that is generally 
ascending
Legs that feel unstable or rubbery are an initial sign
Reflexes disappear or are greatly lessened 
Diffuse pain in shoulders, neck, back/spine occurs in 
nearly half of patients
Deep or aching pain in muscles
Weakness progresses over hours to days
Lack of vasomotor control*
Dysesthesias in the limbs are common (tingling)
Lower extremities are more likely to be affected than 
are upper extremities
Facial diparesis is noted in 50% of cases
If lower cranial nerves are affected, patients may have 
trouble maintaining an airway and managing 
secretions
Hauser, S.,  Harrison’s Principles of 
Internal Medicine, 20th edition, 2018, 
Chapter 439.




70% of GBS cases occur between 1-3 weeks after acute infection
Generally, respiratory or gastrointestinal infection
20-30% of cases in Europe, Australia, or the United States have been shown to be due to Campylobacter jejuni
Other causes include cytomegalovirus, herpes simplex, and Epstein-Barr virus infections, human immunodeficiency virus 
(HIV), zika virus, hepatitis E, Mycoplasma pneumoniae, and Hemophilus influenzae 
Immunizations
1976 swine influenza vaccine
Recent flu vaccines 
Older rabies vaccines Hauser, S.,  Harrison’s Principles of 
Internal Medicine, 20th edition, 
2018, Chapter 439. 
Willison, H. The Lancet, August 
2016,  388(10045):717-727.
van Doorn, P. Journal of clinical 







2.  An autoimmune 
response is triggered, which 
targets the peripheral 
nerves and their spinal 
roots
3.  Beginning 1-2 weeks 
after the antecedent event, 
illness rapidly progresses 
and may worsen for a few 
hours to 28 days
4.   A clinical plateau is 
reached, after which patients 
begin to recover (takes 
months to years)
Hauser, S.,  Harrison’s Principles of Internal 
Medicine, 20th edition, 2018, Chapter 439. 
Willison, H. The Lancet, August 2016,  
388(10045):717-727.
MOLECULAR IMPOSTERS
Auto-antibody attack on the axolemma of nerves is likely due to molecular mimicry of the pathogen and surface 
molecules on the nerve
The mimics are glycans on lipooligosaccharides (LOS) of pathogens which are structurally similar to glycans that 
reside on gangliosides of nerves
However, only a small percentage of C. jejuni strains have glycans which mimic gangliosides on their LOS
In AMAN , neuronal damage is caused by subsequent recruitment of macrophages, complement changes, and 
addition of membrane attack complex to the axolemma
Nerve function is lost due to exposure of the nerve at nodes of Ranvier and nerve terminals
Willison, H. The Lancet, August 2016,  
388(10045):717-727.
LOCATION OF ATTACK
The location of damage dictates what recovery will look like for patients
Acute Inflammatory Demyelinating Polyneuropathy (AIDP)
Injury occurs at Schwann cells and the myelin sheath
Recovery occurs via peripheral nerve remyelination
Acute Motor Axonal Neuropathy (AMAN)
Main target is the axolemma (nerve axon membranes) 
Antibodies are produced against  GM1 and GD1a (neuronal membrane gangliosides)
Recovery may or may not occur, depending if the entire length of the nerve is damaged
Slow recovery may occur via axonal regeneration
Willison, H. The Lancet, August 2016,  
388(10045):717-727.
INFLAMMATION AND DEMYELINATION
There are more triggers for Acute Inflammatory Demyelinating Polyneuropathy (AIDP) than for other subtypes
Antibody biomarkers are unknown despite studies to pinpoint the specific nerve antigens
This type of GBS may have a wider range of auto-antibodies, that target both glycolipid and protein components 
of nerves
Antibodies noted have been located near nodes of Ranvier
Glycolipids expressed in the glial membranes are favored as antigens, and some findings support this
Some also suggest that this type of damage may be T-cell-mediated, although there is little evidence to show that 
T-cells respond to myelin proteins
Willison, H. The Lancet, August 2016,  
388(10045):717-727.
VACCINATION: PREVENTION OR TRIGGER?
1976 vaccinations against H1N1 influenza virus: 1 in 100,000 chance of having GBS
2009 studies indicate that H1N1 vaccinations resulted in a 1.6 in 1,000,000 chance of having GBS
Despite concerns, it does not appear that influenza vaccinations have caused additional episodes of GBS in patients 
with a history of GBS
Vaccination is usually appropriate for patients with a history of GBS, with a few exceptions
Those who had vaccination-related GBS
Those who have recently had GBS (within 3 months)
Influenza vaccination may actually prevent GBS
Infection with the influenza virus itself can be an precipitating event 
Willison, H. The Lancet, August 2016,  
388(10045):717-727.
LABORATORY VALUES
Protein in Cerebrospinal Fluid (CSF): 100-1,000 mg/dl
Not seen if in early stages of disease (≤ 48 hours)
Rarely, may see brief increase in lymphocytes (10-100/microL)
Electrodiagnostic Signs
May not exist in early stages of GBS
Decreased amplitude of the compound muscle action potentials (CMAPs)
With no conduction slowing associated 
Hauser, S.,  Harrison’s Principles of 




Lack of fever or systemic symptoms
Presence of an antecedent event
Patient displays a disease pattern of quickly progressing weakness, loss of reflexes, and paralysis
Brighton Collaboration Criteria
Break diagnosis into tiers of ‘certainty’
Validated by additional research
Electrodiagnostic Signs and CSF Labs 
Important in confirming, but recommend starting treatment if suspect GBS and unable to confirm via labs
Hauser, S.,  Harrison’s Principles 
of Internal Medicine, 20th edition, 
2018, Chapter 439.
Willison, H. The Lancet, August 
2016,  388(10045):717-727.
BRIGHTON COLLABORATION CRITERIA
Level 1 Diagnostic Certainty Level 2 Diagnostic Certainty Level 3 Diagnostic Certainty
Bilateral, flaccid limb weakness PLUS Bilateral, flaccid limb weakness PLUS Bilateral, flaccid limb weakness PLUS
Absent or decreased deep tendon 
reflexes in affected limbs PLUS
Absent or decreased deep tendon 
reflexes in affected limbs PLUS
Absent or decreased deep tendon 
reflexes in affected limbs PLUS
Electrophysiologic findings reflect GBS 
PLUS
CSF total white count <50 
cells/microL (+/- protein elevation) 
PLUS
Monophasic pattern of illness and 
between 12 hours-28 days from onset 
to clinical plateau
Monophasic pattern of illness and 
between 12 hours-28 days from onset 
to clinical plateau PLUS
Monophasic pattern of illness and 
between 12 hours-28 days from onset 
to clinical plateau
No alternative diagnosis identified
No alternative diagnosis identified OR, if CSF results unavailable or 
unable to be collected: 
Cytoalbuminologic dissociation Electrophysiologic studies reflect GBS 
PLUS
No alternative diagnosis identified
Hauser, S.,  Harrison’s Principles of 
Internal Medicine, 20th edition, 
2018, Chapter 439, based on table 
439-3.
SUMMARY OF AMERICAN ACADEMY OF NEUROLOGY GUIDELINES
Recommends IV immunoglobulin for non-ambulatory patients
Appropriate if patients are within 2 to 4 weeks of first experiencing GBS symptoms
Recommends plasma exchange for non-ambulatory patients
Appropriate to treat within 4 weeks of onset of GBS symptoms
May also consider for ambulatory patients within 2 weeks of onset of GBS symptoms
No recommendation can be made for corticosteroid use or combination regimens
Plasma exchange and IV immunoglobulin are appropriate for use in pediatric patients
Hughes, R., Neurology, 61(6):736-740
SUPPORTIVE CARE
Pain Management
No evidence is available to recommend a specific therapy
Critical Care Support and Monitoring
Frequent turning and skin care
Venous Thromboembolism (VTE) Prophylaxis
Chest Physiotherapy
Regular range-of-motion exercises
Monitor for autonomic issues
Hauser, S.,  Harrison’s Principles of 
Internal Medicine, 20th edition, 2018, 
Chapter 439.
Willison, H. The Lancet, August 
2016,  388(10045):717-727.
SUPPORTIVE CARE: MECHANICAL VENTILATION
Mechanical Ventilation 
Required by nearly 1/3 of patients 
Associated with
More rapid progression of illness
Increased severity of weakness
Bulbar/facial weakness
Erasmus GBS Respiratory Insufficiency Score (EGRIS)
Should be used upon admission to see if the patient will likely need mechanical ventilation
Hauser, S.,  Harrison’s Principles of 
Internal Medicine, 20th edition, 2018, 
Chapter 439.




Ensure that patient is carefully monitored during recovery
Avoid in-hospital complications
Plasma Exchange
Complete therapy within the first month after onset of symptoms
Treatment should be completed in the first two weeks, if possible
IV Immunoglobulin
Complete therapy within 2-4 weeks after onset of symptoms
Willison, H. The Lancet, August 2016,  
388(10045):717-727.
Hughes, R., Neurology, 61(6):736-740
NON-PHARMACOLOGIC TREATMENT
Plasma Exchange
Allows for removal of inflammatory factors, including complement and auto-antibodies
2-3 L of plasma should be exchanged, depending on bodyweight
The best-studied regimen is 5 plasma exchanges completed over a 2-week period for patients with GBS who 
cannot walk without assistance
2 plasma exchanges may be beneficial even in ambulatory patients
Anticoagulation is needed (generally heparin)
Replacement fluid may be albumin, albumin with saline or plasma expanders, or fresh frozen plasma
Willison, H. The Lancet, August 
2016,  388(10045):717-727.
Lehmann H., Arch 
Neurol.2006;63(7):930–935.
Hughes, R., Neurology, 61(6):736-
740








If use filtration method
Hypotension
Hemolysis 
Lehmann, H., Arch 
Neurol.2006;63(7):930–935.
PHARMACOLOGIC TREATMENT
Multiple randomized clinical trials have demonstrated that immunotherapy using either plasma exchange or IV 
immunoglobulin is effective
Imperative that treatment be started quickly
Unknown if immunotherapy has any effect after 2 weeks of illness
High-Dose Intravenous Immunoglobulin
Recommended dose of 2g/ kg body weight in 5 divided doses over 5 days
Some propose the mechanism of action is that IVIG anti-idiotypic antibodies help to destroy GBS autoantibodies
Effective if started within 2 weeks of symptoms in patients unable to walk
Hauser, S.,  Harrison’s Principles of 
Internal Medicine, 20th edition, 2018, 
Chapter 439.
Willison, H. The Lancet, August 2016,  
388(10045):717-727.




A pooled serum product used to replace antibodies
Designed to deliver human isotype G immunoglobulin
IV Ig can be used for numerous indications, in immunology, rheumatology, neurology, hematology, and more
Available products include:
IV solutions--Bivigam, Flebogamma 10% DIF, Flebogamma 5% DIF, Gammagard Liquid, Gammaplex 5%, Gammaplex 10%, 




van Doorn, Journal of clinical immunology, 30 Suppl 1(Suppl 1), S74-8.   
Jolles, S., Clinical and experimental immunology, 142(1), 1-11.
Miller, M. "Intravenous Immunoglobulin (IV IG) Internal Medicine: A Guide 
to Clinical Therapeutics. IBM 
Micromedex: “Immune Globulin”. Micromedex Solutions [databaseonline]. 
Truven Health Analytics, Inc.; 2018.                                 Perez, E., J 
Allergy Clin Immunol, 139(1):S1-S46.                            Chaigne, B., 
Apheresis and Transfusion Science, 56 (1): 45-49. 
MECHANISM OF ACTION
Multiple proposed mechanisms exist, but it is unclear how IV immunoglobulin treats GBS
Anti-cytokine antibodies or anti-idiotypic antibodies in IV Ig may target autoantibodies and cytokines
IV Ig might interfere with aspects of T-cell regulation and the complement cascade
Downregulation of activating factors for B-cells
Prevention of antibody attacks on Schwann cells via blockage of macrophage Fc receptors
Upregulation of B-cell component Fc-gamma IIB
Some also think that elevated levels of immunoglobulins help to speed the breakdown of immunoglobulin G
Miller, M. "Intravenous 
Immunoglobulin (IVIg)." Internal 
Medicine: A Guide to Clinical 
Therapeutics.
Hughes, R., Cochrane Systematic  
Review.
IV IMMUNOGLOBULIN MONITORING PARAMETERS
Hemolysis
Hct and Hgb
Transfusion-related acute lung injury (TRALI)
Anti-neutrophil antibodies and/or anti-HLA antibodies 
Renal function
Watch urine output, blood urea nitrogen, and serum creatinine
Signs of hyperviscosity
Increased triglycerides,  presence of cryoglobulins and monoclonal gammopathies
Miller, M. "Intravenous Immunoglobulin (IVIg)." Internal 
Medicine: A Guide to Clinical Therapeutics.                     BM 
Micromedex: “Immune Globulin”. Micromedex Solutions 
[database online]. Truven Health Analytics, Inc.; 2018.                                                                      




Usually mild, cease when infusion is stopped
Chills, fever, headache, flushing, tight chest, vomiting, diarrhea, tachycardia, blood pressure fluctuations
Anaphylaxis is possible
Acute Kidney Failure
Risk Factors for side effects: 
First dose of IV Ig, high rate of infusion, elderly, dehydrated/volume depleted
Prevention 
Diphenhydramine (1mg/kg/dose), acetaminophen (15 mg/kg/dose), antiemetic
Decrease infusion rate
Keep epinephrine on hand
Miller, M. "Intravenous Immunoglobulin 
(IVIg)." Internal Medicine: A Guide to 
Clinical Therapeutics.
Octapharma USA, Inc. Octagam 10%[ 
Package Insert]. FDA.gov.                 Perez, 
E., J Allergy Clin Immunol, 139(1):S1-S46. 
ADMINISTRATION
Give infusion via a separate IV line
Do not combine IV immunoglobulin products from different manufacturers
Allow the product to reach room temperature prior to infusion
Administer at the slowest rate if concerns for kidney function or in elderly patients
Miller, M. "Intravenous Immunoglobulin 
(IVIg)." Internal Medicine: A Guide to Clinical 
Therapeutics.
Lexi-Drugs OnlineTM. “ Immune Globulin” Lexi-
Comp OnlineTM. Hudson (OH): Lexi-Comp, 
Inc.; 2018
Octapharma, USA, Inc. Octagam10%  
[Package insert]. 
Infusion Rate (Octagam 
10%)
mg/kg/min ml/min/kg
First 30 minutes 1mg/kg/min 0.01 ml/kg/min
Maximum rate ≤12 mg/kg/min ≤0.12 ml/kg/min
RELEVANT COUNSELING POINTS
Monitor for Transfusion-related Acute Lung Injury (TRALI)
Thrombosis may occur
Do not administer live vaccines within 3 months of the infusion
Aseptic Meningitis
Headache, sore or stiff neck, photosensitivity
Hemolysis
Elevated heart rate, yellow skin, fatigue
Renal Issues
Shortness of breath, decreased production of urine, weight fluctuation/gain due to fluid
CSL Behring. Immune Globulin 
Intravenous (Human), 10% Liquid, 
Privigen [Product Insert]. FDA.gov
Octapharma USA, Inc. Octagam 10%[ 
Package Insert]. 
“SAFETY AND EFFICACY OF ECULIZUMAB IN GUILLAIN-BARRÉ SYNDROME: A
MULTICENTRE, DOUBLE-BLIND, RANDOMISED PHASE 2 TRIAL”
Inclusion Criteria: 
≥ 18 years of age
First dose of eculizumab given within 2 weeks of symptoms, but 
after last IV immunoglobulin dose
Not able to walk without assistance (>5 meters)
Within 2 weeks of the start of GBS symptoms




Form of neuropathy other than GBS
Immunosuppression 4 weeks prior to study
History of eculizumab use for GBS
History of meningococcal infection
Misawa, S., The Lancet 
Neurology, 17(6), 519-529
Yamaguchi, N.,JMIR Research 
Protocols, 5(4):e210
Japanese eculizumab trial for Guillain-Barre’ Syndrome” (JET-GBS trial)
Purpose: To examine efficacy and safety of eculizumab in Guillain-Barre’ Syndrome
Eculizumab-a humanized monoclonal antibody that prevents complement activation
JET-GBS TRIAL CONTINUED
Subjects received either placebo or eculizumab 900 mg via a weekly IV infusion for 4 weeks (in addition to IVIG)
The first dose of eculizumab had to be started before the last dose of IV immunoglobulin
Nerve conduction tests and vital capacity tests were done during observation
Subjects also received antibiotic prophyaxis, due to increased risk of infection
N=34
Primary endpoint: 
Subjects able to walk by week 4 (functional grade 2 or lower) 
Not found to be statistically significant
Misawa, S., The Lancet 
Neurology, 17(6), 519-529
Yamaguchi, N.,JMIR Research 
Protocols, 5(4):e210
ECULIZUMAB (SOLIRIS)
Monoclonal, humanized Immunoglobulin G antibody designed to bind to complement protein (C5) to stop 
formation of membrane attack complex (MAC)
Meningococcal vaccination is necessary 2 weeks prior to treatment
May use antibiotic prophylaxis if not possible to vaccinate
Guillain-Barre’ Syndrome is not an FDA-approved use at this time
Adverse effects:
Nausea, headache, back pain, nasopharyngitis
Contraindications to use:
Unvaccinated against Neisseria meningitidis 
Active Neisseria meningitidis infection
Lexi-Drugs OnlineTM. “ Eculizumab” Lexi-Comp 
OnlineTM. Hudson (OH): Lexi-Comp, Inc.; 2018. 
Alexion Pharmaceuticals. SolirisTM (eculizumab) 
concentrated solution for intravenous infusion 
[prescribing information]. 
ECULIZUMAB: 
ADMINISTRATION AND COUNSELING POINTS
Administration
Give over 35 minutes as an IV infusion
Dilute to 5mg/ml using NS, 1/2NS, D5W, or Ringer’s solution
Let the solution reach room temperature prior to giving the infusion
Monitoring
Lactate dehydrogenase (LDH),  AST, serum creatinine, CBC (with differential)
Infusion reactions- watch for anaphylaxis
Counseling
Educate regarding symptoms of meningococcal infection
Lexi-Drugs OnlineTM. “ Eculizumab” Lexi-
Comp OnlineTM. Hudson (OH): Lexi-Comp, 
Inc.; 2018. 
Alexion Pharmaceuticals. SolirisTM
(eculizumab) concentrated solution for 
intravenous infusion [prescribing 
information]. 
“A RANDOMIZED TRIAL COMPARING INTRAVENOUS IMMUNE GLOBULIN 
AND PLASMA EXCHANGE IN GUILLAIN-BARRE’ SYNDROME”
Purpose:  To determine if treatment with IV immune 
globulin is as effective as plasma exchange in Guillain-Barre’ 
Syndrome
Exclusion criteria: 
Allergy to blood products
Immunosuppressive therapy
Selective IgA deficiency
History of Guillain-Barre’ Syndrome
Pregnancy
Immunosuppression




Plasma Exchange over 1-2 weeks
0.4 g/kg Gammagard for 5 days
Inclusion Criteria:
Able to participate in study within 2 weeks of onset of GBS
Unable to walk independently
Met diagnostic criteria for Guillain-Barre’ Syndrome
Van der Meche’,F., The New 
England Journal of 
Medicine, 326(1), 1123-1129.
RESULTS OF TRIAL STUDYING IV IMMUNE GLOBULIN VERSUS 
PLASMA EXCHANGE
Primary outcome:
51% of patients treated with IV immunoglobulin had improved by 1+ functional grade 4 weeks after treatment, as compared to 
30% of patients treated with plasma exchange (p=0.024)
Secondary outcomes:
Median time to recovery of ambulation for patients treated with IV immunoglobulin was 55 days, compared to 69 days for 
patients treated with plasma exchange (p=0.07)
Patients receiving plasma exchange had more treatment-related complications compared to those receiving IV 
immunoglobulin (16 pts versus 5; p <0.01)
27% of patients receiving IV immunoglobulin needed mechanical ventilation, as compared to 42% of those receiving 
plasma exchange (P<0.05)
Van der Meche’,F., The New England 
Journal of Medicine, 326(1), 1123-1129.
TREATMENT-RELATED FLUCTUATIONS
Worsening of GBS after initial stabilization or treatment is referred to as a treatment-related fluctuation (TRF)
10% of patients experience a TRF
TFRs generally occur within two months of treatment
Presentation varies-some have continued worsening after 4 weeks, while others have multiple episodes of worsening
Patients who respond this way may need longer treatment, as they may have permanent nerve damage or 
blockade
Repeated treatment with IV immunoglobulin does show benefit in these patients
IV Ig 2g/kg (divided into 2-5 doses)
Willison, H. The Lancet, August 2016,  
388(10045):717-727.
Thivakaran, T. Journal of neurosciences in 
rural practice, 2(2), 168-70
RECOVERY AND SEQUELAE
Despite immunotherapy, patients with GBS often face long, painful recoveries
Demyelination recovery
Axonal damage
The majority of recovery occurs in the first 12 months, but may continue for 3+ years
GBS is costly: $100, 000+ for medical bills, and an estimated $300,000+ in lost productivity
Incomplete recovery, ongoing fatigue and pain are possible sequelae
20% of patients with GBS are unable to walk without help 6 months after the initial symptoms
Persistent axonal loss contributes to pain and fatigue
67% of patients will have chronic fatigue
Pediatric patients are less likely to have severe sequelae
Willison, H. The Lancet, August 
2016,  388(10045):717-727.
Hughes, R., Neurology, 
61(6):736-740
CONCLUSIONS:
ROLE OF THE PHARMACIST
Reference available guidelines and recommend appropriate therapy
Help to answer questions about rate and administration of IV immunoglobulin products
Educate staff and patients about the risks associated with IV immunoglobulin
Ensure that patients receive any necessary pre-medications prior to IV immunoglobulin infusion
Diphenhydramine
Acetaminophen
Discuss data for eculizumab use, and be prepared to recommend appropriate antibiotic prophylaxis if this option 
is chosen
Being knowledgeable about costs associated with these therapies benefits your patients!
CONCLUSIONS
Guillain-Barre’ Syndrome is an umbrella term for a number of demyelinating diseases or axonopathies
The cause and mechanism of damage is not clear, but may involve molecular mimicry resulting in autoimmune 
attack
Recovery may be complete or patients may have permanent sequelae
Supportive care is particularly important, including careful monitoring of vital signs and mechanical ventilation
Two treatment options are recommended:
Plasmapheresis
IV Immunoglobulin 2g/kg given in 2-5 divided doses on consecutive days
Eculizumab may also be an option, but it has not yet been evaluated in the guidelines
PATIENT CASE WRAP-UP
No electrophysiology studies can be performed for at least 48 hours. Based on the pattern of disease and the 
Brighton Collaboration Criteria, the physician feels confident that this is Guillain-Barre’ Syndrome. 
Should treatment be recommended?
What do you recommend? Include dose and directions. 
Name: ________________________ 
 
Guillain-Barre’ Syndrome Quiz 
1. CB is a 25 year old male who will be receiving Octagam 10% for treatment of GBS. He 
has no risk factors for an adverse reaction to IV immunoglobulin. What is the maximum 
infusion rate for this product, assuming that CB is able to tolerate the infusion? 
a. 4 mg/kg/min 
b. 1mg/kg/min 
c. ≤12 mg/kg/min 
d. ≤8 mg/kg/min 
 
2. Based on the information presented, what are acceptable forms of Guillain-Barre’ 
Syndrome treatment for pediatric patients? 
a. Plasma exchange  
b. Eculizumab  
c. IV immunoglobulin  
d. All of the above 
e. A and C 
 
3. True or False: Receiving an influenza vaccine is contraindicated for ALL patients with a 
previous history of Guillain-Barre’ Syndrome from any cause.  
 
4. True or False: Both plasma exchange and IV immunoglobulin products are recommended 
by for use in sequence or together.  
 
 
5. A 45 year-old patient with no past medical history presents with ascending weakness and 
loss of reflexes for the past 2 days. She does not take any medications. She notes that she 
had a “stomach bug” 3 weeks ago. CSF lab results are pending and electrodiagnostic 
studies are unable to be performed until the technician arrives tomorrow morning. The 
physician believes that this is Guillain-Barre’ Syndrome. Should the patient be treated for 
probable Guillain-Barre’ Syndrome? 
a. Yes, this patient should be treated.  
b. No, you should wait to confirm the diagnosis with labs.  
c. There are no medications or treatments that can help with GBS 
d. Tell the patient to go home, her weakness is likely just a symptom of the 
“stomach bug” that she had previously 
Guillain-Barre’ Syndrome Seminar References 
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